6-(2,6-dimethylphenyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one | 847950-62-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 6-(2,6-dimethylphenyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one
• 英文别名: 6-(2,6-dimethylphenyl)-2-[4-(4-methylpiperazino)phenylamino]-8,9-dihydro-imidazolo[1,2-a]pyrimido[5,4-e]pyrimidin-5-one；7-(2,6-Dimethylphenyl)-12-[4-(4-methylpiperazin-1-yl)anilino]-2,5,7,11,13-pentazatricyclo[7.4.0.02,6]trideca-1(13),5,9,11-tetraen-8-one
• CAS: 847950-62-3
• 化学式: C₂₇H₃₀N₈O
• 分子量: 482.588
• InChiKey: KJIILNMNSDTEPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  36
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  80.2
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  6-(2,6-dimethylphenyl)-2-methanesulphonyl-8,9-dihydroimidazolo[1,2-a]pyrimido[5,4-e]pyrimidin-5-one 、 4-(4-甲基哌嗪)苯胺 以 异丙醇 为溶剂， 反应 1.0h， 生成 6-(2,6-dimethylphenyl)-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one
  参考文献：
  名称：

  [EN] SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE
  [FR] COMPOSES HETEROCYCLIQUES SUBSTITUES ET LEURS METHODES D'UTILISATION

  摘要：

  本发明涉及四环嘧啶或吡啶或其药用盐或衍生物。还包括使用四环嘧啶或吡啶的方法，包括用于治疗炎症、抑制T细胞激活和增殖、关节炎、器官移植、缺血再灌注损伤、心肌梗死、中风、多发性硬化、炎症性肠病和其他相关疾病的方法，在这些方法中向受试者施用上述化合物的治疗有效量。

  公开号：

  WO2005021551A1

文献信息

• Substituted heterocyclic compounds and methods of use
  申请人：Nunes J. Joseph

  公开号：US20050070554A1

  公开（公告）日：2005-03-31

  The present invention relates to tetracyclic pyrimidines or pyridines or pharmaceutically-acceptable salts or derivatives thereof. Also included are methods of use of the tetracyclic pyrimidines or pyridines including use related to treating inflammation, inhibiting T cell activation and proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease and many other related disorders in a subject, the methods comprising administering a therapeutically-effective amount a compound as described above to the subject.

  本发明涉及四环嘧啶或吡啶或其药学上可接受的盐或衍生物。还包括使用四环嘧啶或吡啶的方法，包括用于治疗炎症、抑制T细胞活化和增殖、关节炎、器官移植、缺血或再灌注损伤、心肌梗死、中风、多发性硬化症、炎症性肠病和许多其他相关疾病的方法，在该方法中向受试者施用上述化合物的治疗有效量。
• 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND
  申请人：Impact Therapeutics, Inc

  公开号：EP3543242A1

  公开（公告）日：2019-09-25

  Disclosed are 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R1-R7 are defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.

  所公开的是 8,9-二氢咪唑并[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮化合物，具体由式 I 表示： 或其药学上可接受的盐或原药，其中 A 和 R1-R7 在此定义。具有式 I 的化合物是 Wee1 激酶抑制剂。因此，本公开的化合物可用于治疗由 Wee1 活性异常引起的疾病。
• 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones
  申请人：IMPACT THERAPEUTICS, INC.

  公开号：US10703759B2

  公开（公告）日：2020-07-07

  Disclosed are 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R1-R7 are defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.

  所公开的是 8,9-二氢咪唑并[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮化合物，具体由式 I 表示： 或其药学上可接受的盐或原药，其中 A 和 R1-R7 在此定义。具有式 I 的化合物是 Wee1 激酶抑制剂。因此，本公开的化合物可用于治疗由 Wee1 活性异常引起的疾病。
• SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE
  申请人：AMGEN INC.

  公开号：EP1664053A1

  公开（公告）日：2006-06-07
• 8,9-DIHYDROIMIDAZO[1,2-a]PYRIMIDO[5,4-e]PYRIMIDIN-5(6H)-ONES
  申请人：IMPACT THERAPEUTICS, INC.

  公开号：US20190308984A1

  公开（公告）日：2019-10-10

  Disclosed are 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R 1 -R 7 are defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.